pI: 10.7095 |
Length (AA): 212 |
MW (Da): 24572 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
62 | 184 | 1nkw (H) | 37 | 158 | 32.00 | 0 | 1 | 0.9 | 0.86 |
67 | 212 | 1j3a (A) | 2 | 131 | 19.00 | 0 | 0.97 | 0.62 | -0.28 |
51 | 195 | 4wfa (G) | 1 | 144 | 28.00 | 0 | 1 | 0.997062 | 0.1 |
53 | 197 | 5dm6 (G) | 30 | 171 | 28.00 | 0 | 1 | 1.00996 | -0.17 |
64 | 208 | 1vq8 (J) | 7 | 137 | 17.00 | 0 | 0.72 | 0.704962 | 0.11 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 32 hs, Oocyst, Male Gametocyte. | Otto TD Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, intra-erythrocytic - 24 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, merozoite, early schizont, late trophozoite, Sporozoite. | Otto TD PlasmoDB Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | early trophozoite, late schizont, Ring. | PlasmoDB Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Female Gametocyte. | Lasonder E |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Ortholog group members (OG5_127268)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G01790 | large subunit ribosomal protein L13 |
Arabidopsis thaliana | AT1G78630 | 50S ribosomal protein L13 |
Babesia bovis | BBOV_IV005700 | 50S ribosomal protein L13, putative |
Candida albicans | CaO19.10856 | likely mitochondrial ribosomal protein similar to S. cerevisiae MRPL23 (YOR150W) large subunit protein (E. coli L13) |
Candida albicans | CaO19.3348 | likely mitochondrial ribosomal protein similar to S. cerevisiae MRPL23 (YOR150W) large subunit protein (E. coli L13) |
Caenorhabditis elegans | CELE_F13G3.11 | Protein MRPL-13 |
Chlamydia trachomatis | CT_125 | 50S ribosomal protein L13 |
Dictyostelium discoideum | DDB_G0274959 | hypothetical protein |
Drosophila melanogaster | Dmel_CG10603 | mitochondrial ribosomal protein L13 |
Escherichia coli | b3231 | 50S ribosomal subunit protein L13 |
Echinococcus granulosus | EgrG_001032000 | ribosomal protein L13 |
Echinococcus multilocularis | EmuJ_001032000 | ribosomal protein L13 |
Homo sapiens | ENSG00000172172 | mitochondrial ribosomal protein L13 |
Leishmania braziliensis | LbrM.20.3270 | 50S ribosomal protein L13-like protein |
Leishmania donovani | LdBPK_343470.1 | 50S ribosomal protein L13-like protein |
Leishmania infantum | LinJ.34.3470 | 50S ribosomal protein L13-like protein |
Leishmania major | LmjF.34.3680 | 50S ribosomal protein L13-like protein |
Leishmania mexicana | LmxM.33.3680 | 50S ribosomal protein L13-like protein |
Mycobacterium leprae | ML0364 | Probable 50S ribosomal protein L13 RplM |
Mus musculus | 68537 | mitochondrial ribosomal protein L13 |
Mycobacterium tuberculosis | Rv3443c | 50S ribosomal protein L13 RplM |
Mycobacterium ulcerans | MUL_0864 | 50S ribosomal protein L13 |
Neospora caninum | NCLIV_047460 | 50S ribosomal protein L13, putative |
Oryza sativa | 4325555 | Os01g0749200 |
Oryza sativa | 4338199 | Os05g0243300 |
Plasmodium berghei | PBANKA_0311100 | mitochondrial large ribosomal subunit, putative |
Plasmodium falciparum | PF3D7_0214200 | mitochondrial ribosomal protein L13 precursor, putative |
Plasmodium knowlesi | PKNH_0406600 | ribosomal protein L13, putative |
Plasmodium vivax | PVX_002825 | 50S ribosomal protein L13, putative |
Saccharomyces cerevisiae | YOR150W | mitochondrial 54S ribosomal protein YmL23 |
Schistosoma japonicum | Sjp_0202660 | ko:K02871 large subunit ribosomal protein L13, putative |
Schistosoma mansoni | Smp_121790.1 | 50S ribosomal protein L13 |
Schmidtea mediterranea | mk4.000263.07 | 39S ribosomal protein L13, mitochondrial |
Trypanosoma brucei gambiense | Tbg972.4.900 | 50S ribosomal protein L13, putative |
Trypanosoma brucei | Tb927.4.1070 | Mitochondrial ribosomal protein L13 |
Trypanosoma congolense | TcIL3000_4_690 | 50S ribosomal protein L13, putative |
Trypanosoma cruzi | TcCLB.503929.20 | ribosomal protein L13, putative |
Trypanosoma cruzi | TcCLB.506405.110 | ribosomal protein L13, putative |
Toxoplasma gondii | TGME49_225240 | 50S ribosomal protein L13, putative |
Treponema pallidum | TP1025 | 50S ribosomal protein L13 |
Theileria parva | TP01_0369 | 60S ribosomal protein L13, putative |
Wolbachia endosymbiont of Brugia malayi | Wbm0574 | 50S ribosomal protein L13 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.1070 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.1070 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.1070 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.4.1070 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
b3231 | Escherichia coli | essential | goodall |
CELE_F13G3.11 | Caenorhabditis elegans | embryonic lethal | wormbase |
PBANKA_0311100 | Plasmodium berghei | Essential | plasmo |
TGME49_225240 | Toxoplasma gondii | Probably essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.7